Roche Acquires TMEM16A Portfolio for Cystic Fibrosis Treatment

Roche Acquires TMEM16A Portfolio for Cystic Fibrosis Treatment

Cystic Fibrosis Weekly Update Contents: Roche Acquires TMEM16A Portfolio for CF Treatment Tobacco Smoke Exposure Limits Symdeko Benefit in Pediatric CF Patients Roche Acquires TMEM16A Portfolio for CF Treatment Oct 09, 2020 07:00 am | Sara Guariglia Roche has acquired Enterprise Therapeutics’s TMEM16A potentiator portfolio, which includes ETD002, a therapeutic candidate being evaluated in Phase 1 clinical trials for the treatment of cystic fibrosis (CF). The TMEM16A portfolio is focused on treatments for CF and other severe respiratory disorders characterized by excessive mucus congestion. Genentech, a member of the Roche Group, now […] The post Roche Acquires TMEM16A Portfolio for CF Treatment appeared first on Cystic Fibrosis News Today. Read More Tobacco Smoke Exposure Limits Symdeko Benefit in Pediatric CF Patients Oct 08, 2020 07:00 am | Forest Ray Exposure to tobacco smoke limits the medicinal benefit of Symdeko (tezacaftor/ivacaftor combo) in young patients with cystic fibrosis (CF), according to a recent study. This finding suggests that smoking must be avoided for Symdeko to provide its full benefits. It also suggests that the effects of smoke exposure on next-generation cystic fibrosis transmembrane receptor (CFTR) […] The post Tobacco Smoke Exposure Limits Symdeko Benefit in Pediatric CF Patients appeared first on Cystic Fibrosis News Today. Read More Recent News Lenabasum Fails to Lessen Exacerbations in CF Patients in Phase 2 Trial Same But Different Asks Public to Vote on ‘Glimmer of Hope’ Calendar Photos Twincer Inhaler May Be Better Alternative to Nebulizers for Colistin Treatment Student-Led Konglomerate Games Wins Entrepreneurship Award for CF Therapy Game NTM Infection Rate in Young CF Patients in UK Remains Stable But High, Study Finds